The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

R. Abele, M. Clavel, P. Dodion, U. Bruntsch, S. Gundersen, J. Smyth, J. Renard, M. Van Glabbeke, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

The Early Clinical Trials Cooperative Group of the EORTC conducted several phase II studies with a pyrimidine analogue of deoxycytidine, 5-aza-2′-deoxycytidine (DAC). The drug was given as three consecutive 1 h i.v. infusions of 75 mg/m2, separated by intervals of 7 h; courses were repeated every 5 weeks. A total of 101 eligible patients were studied: 42 with colo-rectal adenocarcinoma, 27 with squamous cell carcinoma of the head and neck, 18 with malignant melanoma and 14 with renal cell carcinoma. Drug-induced toxicities consisted of moderate myelosuppression, and nausea and vomiting. One single partial remission was seen in a patient with malignant melanoma. DAC given in this dose and schedule is devoid of antitumour activity in adult patients with these refractory types of carcinomas.

Original languageEnglish (US)
Pages (from-to)1921-1924
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number12
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

decitabine
Melanoma
Neck
Head
Clinical Trials
Carcinoma
Kidney
Deoxycytidine
Drug-Related Side Effects and Adverse Reactions
Renal Cell Carcinoma
Nausea
Vomiting
Appointments and Schedules
Adenocarcinoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. / Abele, R.; Clavel, M.; Dodion, P.; Bruntsch, U.; Gundersen, S.; Smyth, J.; Renard, J.; Van Glabbeke, M.; Pinedo, H. M.

In: European Journal of Cancer and Clinical Oncology, Vol. 23, No. 12, 1987, p. 1921-1924.

Research output: Contribution to journalArticle

Abele, R. ; Clavel, M. ; Dodion, P. ; Bruntsch, U. ; Gundersen, S. ; Smyth, J. ; Renard, J. ; Van Glabbeke, M. ; Pinedo, H. M. / The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. In: European Journal of Cancer and Clinical Oncology. 1987 ; Vol. 23, No. 12. pp. 1921-1924.
@article{dbb9a532d7bb41558b67d4018ef56f5d,
title = "The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas",
abstract = "The Early Clinical Trials Cooperative Group of the EORTC conducted several phase II studies with a pyrimidine analogue of deoxycytidine, 5-aza-2′-deoxycytidine (DAC). The drug was given as three consecutive 1 h i.v. infusions of 75 mg/m2, separated by intervals of 7 h; courses were repeated every 5 weeks. A total of 101 eligible patients were studied: 42 with colo-rectal adenocarcinoma, 27 with squamous cell carcinoma of the head and neck, 18 with malignant melanoma and 14 with renal cell carcinoma. Drug-induced toxicities consisted of moderate myelosuppression, and nausea and vomiting. One single partial remission was seen in a patient with malignant melanoma. DAC given in this dose and schedule is devoid of antitumour activity in adult patients with these refractory types of carcinomas.",
author = "R. Abele and M. Clavel and P. Dodion and U. Bruntsch and S. Gundersen and J. Smyth and J. Renard and {Van Glabbeke}, M. and Pinedo, {H. M.}",
year = "1987",
doi = "10.1016/0277-5379(87)90060-5",
language = "English (US)",
volume = "23",
pages = "1921--1924",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "12",

}

TY - JOUR

T1 - The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

AU - Abele, R.

AU - Clavel, M.

AU - Dodion, P.

AU - Bruntsch, U.

AU - Gundersen, S.

AU - Smyth, J.

AU - Renard, J.

AU - Van Glabbeke, M.

AU - Pinedo, H. M.

PY - 1987

Y1 - 1987

N2 - The Early Clinical Trials Cooperative Group of the EORTC conducted several phase II studies with a pyrimidine analogue of deoxycytidine, 5-aza-2′-deoxycytidine (DAC). The drug was given as three consecutive 1 h i.v. infusions of 75 mg/m2, separated by intervals of 7 h; courses were repeated every 5 weeks. A total of 101 eligible patients were studied: 42 with colo-rectal adenocarcinoma, 27 with squamous cell carcinoma of the head and neck, 18 with malignant melanoma and 14 with renal cell carcinoma. Drug-induced toxicities consisted of moderate myelosuppression, and nausea and vomiting. One single partial remission was seen in a patient with malignant melanoma. DAC given in this dose and schedule is devoid of antitumour activity in adult patients with these refractory types of carcinomas.

AB - The Early Clinical Trials Cooperative Group of the EORTC conducted several phase II studies with a pyrimidine analogue of deoxycytidine, 5-aza-2′-deoxycytidine (DAC). The drug was given as three consecutive 1 h i.v. infusions of 75 mg/m2, separated by intervals of 7 h; courses were repeated every 5 weeks. A total of 101 eligible patients were studied: 42 with colo-rectal adenocarcinoma, 27 with squamous cell carcinoma of the head and neck, 18 with malignant melanoma and 14 with renal cell carcinoma. Drug-induced toxicities consisted of moderate myelosuppression, and nausea and vomiting. One single partial remission was seen in a patient with malignant melanoma. DAC given in this dose and schedule is devoid of antitumour activity in adult patients with these refractory types of carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0023573963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023573963&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(87)90060-5

DO - 10.1016/0277-5379(87)90060-5

M3 - Article

C2 - 2449354

AN - SCOPUS:0023573963

VL - 23

SP - 1921

EP - 1924

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 12

ER -